PHILADELPHIA – If FDA's John Jenkins could start the breakthrough therapies program again, he probably would make it tougher for sponsors to gain the designation.
Jenkins, director of the Office of New Drugs, said June 30 during a session at the Drug Information Association annual meeting that it remains an open question whether the agency...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?